T1	Concept 0 4	CA12
T2	Action 24 39	drug resistance
T3	Concept 52 58	cancer
A1	Emphasized T3
T4	Action 174 187	overexpressed
T5	Concept 191 194	FLC
R1	subject Arg1:T2 Arg2:T1	
R3	in-context Arg1:T4 Arg2:T5	
R4	subject Arg1:T4 Arg2:T1	
R2	in-context Arg1:T2 Arg2:T3	
T6	Concept 248 261	42-108 46 hpi
T7	Concept 224 228	cell
T8	Concept 215 223	Infected
R5	is-a Arg1:T6 Arg2:T7	
T10	Action 239 247	detected
R6	has-property Arg1:T6 Arg2:T8	
R7	subject Arg1:T10 Arg2:T6	
T9	Concept 267 275	patients
T11	Action 281 289	received
T12	Concept 290 304	glucocorticoid
T13	Concept 312 338	intravenous immunoglobulin
R8	subject Arg1:T11 Arg2:T9	
R9	target Arg1:T11 Arg2:T12	
R10	target Arg1:T11 Arg2:T13	
T14	Concept 401 419	regional disparity
T15	Concept 423 431	COVID-19
T16	Concept 435 444	Chongqing
R11	in-place Arg1:T15 Arg2:T16	
R12	has-property Arg1:T15 Arg2:T14	
T17	Concept 598 600	9%
T18	Concept 608 628	infected individuals
T19	Concept 663 692	infection fatality risk (IFR)
T21	Concept 775 788	0.5% to 0.8%.
T22	Concept 633 644	ascertained
T23	Concept 649 657	reported
R13	has-property Arg1:T18 Arg2:T22	
R14	has-property Arg1:T18 Arg2:T23	
R15	in-context Arg1:T17 Arg2:T18	
R16	entails Arg1:T17 Arg2:T19	
R17	has-property Arg1:T19 Arg2:T21	
